Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50090-7468

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 50090-7468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 01)

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 02)

This text discusses the impact of intrinsic factors such as renal and hepatic impairment, as well as population description on the pharmacokinetics of Desvenlafaxine. It includes calculations and ratios related to Cmax (maximum concentration) and AUC (area under the curve) among different subgroups like renal impairment, hepatic impairment, and varied gender populations. The data presented in the text is utilized to evaluate the influence of these factors on the pharmacokinetics of Desvenlafaxine.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 03)

This text provides information on the effect of other drugs on Desvenlafaxine pharmacokinetics, specifically focusing on CYP3A4 inhibitors such as Ketoconazole. The geometric mean ratios and confidence intervals for different parameters are presented in the table. The data suggests that Ketoconazole has a notable impact on the pharmacokinetics of Desvenlafaxine.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 04)

This text provides information on the effects of Desvenlafaxine on the pharmacokinetics of other drugs, specifically focusing on interactions with CYP2D6, CYP3A, and multiple substrate drugs. It compares the geometric mean ratio with 90% confidence intervals for different drug combinations. The data presented includes changes in metabolites levels for various drugs such as Desipramine, Midazolam, Tamoxifen, and Aripiprazole resulting from the interaction with Desvenlafaxine at different doses.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 05)

This text describes a study showing the estimated proportion of relapses in patients over time since randomization, comparing Desvenlafaxine extended-release tablets to a placebo. The data is presented as a figure showing relapse percentages and the number of days since randomization.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 06)

This text provides information on the estimated proportion of patients with relapse over time using Desvenlafaxine extended-release tablets compared to Placebo, shown as days from randomization. The graph displays the data points for the 50% proportion mark.*

FDA Label Image

Label Image (Lbl500907468)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.